BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

Go back to BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
(NASDAQ: BYSI) Delayed: 0.50 --0 (-0%)
Previous Close $0.50    52 Week High $ 
Open $0.50    52 Week Low $ 
Day High $0.50    P/E N/A 
Day Low $0.50    EPS $ 
Volume 117